Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ?

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2007 by HaEmek Medical Center, Israel.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00489723
First received: June 19, 2007
Last updated: June 20, 2007
Last verified: June 2007
  Purpose

The purpose of this study is to determine if there is a role of prophylactic therapy with tamsulosin prior extracorporeal shock wave lithotripsy to avoid development of steinstrasse. 150 persons that will go to Extracorporeal shock wave lithotripsy will randomize to 2 groups.

Group 1 -of 75 persons will recieve tamsulosin 0.4 mg x 1/d 2 days before the lithotripsy .

Group 2 - of 75 persons will not recieve tamsulosin. 48 hour after the ESWL all 2 group will take abdominal radiograph to evaluate the presence of steinstrasse.


Condition Intervention
Kidney Stones
Drug: tamsulosin 0.4mg

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal

Resource links provided by NLM:


Further study details as provided by HaEmek Medical Center, Israel:

Study Start Date: May 2007
  Eligibility

Ages Eligible for Study:   15 Years to 85 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • size of stone 1-2 cm

Exclusion Criteria:

  • ureteral stricture Presence of internal stent prior use of alfa bloker prior ESWL
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00489723

Contacts
Contact: DORON PEREZ, M.D. +972-4-6495115 perez_do@clalit.org.il

Locations
Israel
Haemek medical center Recruiting
Afula, Israel, 18100
Contact: DORON PEREZ, M.D.    +972-4-6495115    perez_do@clalit.org.il   
Principal Investigator: doron perez, M.D.         
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Principal Investigator: doron perez Urology department: Haemek Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00489723     History of Changes
Other Study ID Numbers: 0056-07-EMC
Study First Received: June 19, 2007
Last Updated: June 20, 2007
Health Authority: Israel: Ethics Commission

Keywords provided by HaEmek Medical Center, Israel:
size of stone 1-2 cm
Pt. with no use of alfa bloker prior ESWL
Pt. without internal stent

Additional relevant MeSH terms:
Kidney Calculi
Nephrolithiasis
Calculi
Kidney Diseases
Pathological Conditions, Anatomical
Urinary Calculi
Urolithiasis
Urologic Diseases
Tamsulosin
Adrenergic Agents
Adrenergic Antagonists
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Urological Agents

ClinicalTrials.gov processed this record on November 20, 2014